3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
9
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lymphatic Abnormalities
2
Lymphangioma, Cystic
2
Lymphangioma
2
Vascular Malformations
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Diseases, Vascular
1
Recurrence
1
Multiple Endocrine Neoplasia Type 1
1
Melanoma
1
Hyperglycemia
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HER2-positive Metastatic Breast Cancer
1
Genetic Diseases, Inborn
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Arteriovenous Malformations
1
Advanced HER2+Breast Cancer
1
Advanced Breast Cancer
1
Interventions
Nivolumab
37
pembrolizumab
26
cabozantinib
26
Specimen Handling
23
Magnetic Resonance Spectroscopy
21
Ipilimumab
19
lenvatinib
13
belzutifan
13
Axitinib
13
CTLA-4 Antigen
10
Sunitinib
9
Radiosurgery
8
Biopsy
8
atezolizumab
7
fludarabine
4
avelumab
4
aldesleukin
4
Immunoglobulin G
4
Disulfides
4
zimberelimab
3
toripalimab
3
tivozanib
3
pazopanib
3
palbociclib
3
durvalumab
3
cemiplimab
3
Surveys and Questionnaires
3
Nephrectomy
3
Everolimus
3
Cyclophosphamide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Alpelisib
×
90 days
×
Clear all
No trials found.